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A b s t r a c t  
Cubosomes are discrete, sub-micron, nano-structured particles of bicontinuous cubic liquid 
crystalline phase. Cubosomes consist of honeycombed (cavernous) structures separating two 
internal aqueous channels and a large interfacial area. They are the biocompatible novel approach 
for the drug delivery system. The controlled release application of these nanoparticles is of a great 
significance in cosmeceutical and pharmaceutical fields. The present study is concerned with the 
design and evaluation of a novel nano-particulate system; cubosomes, loaded with miconazole 
nitrate (MN); which is used as antifungal agent. Cubosome dispersions were formulated by 
emulsification technique using different concentrations of a lipid phase monoolein and the nonionic 
surfactant, Poloxamer 407. The prepared cubosomal dispersions were characterized regarding 
dimensional distribution, particle size, and in vitro drug release. The optimum formulae were 
incorporated in a CMC or HPMC based hydrogels, to form cubosomal hydrogels (cubogels). The 
cubogels were characterized regarding in vitro release of (MN), viscosity and pH. A comparison 
between the cubogels and a commercially available product, Miconaz® cream, was carried out to 
judge their efficacy. The drug release from the commercial preparation was lower than all the 
prepared nano-emulsion based gel formulations. G1 and G8 showed highest drug release percent 
(100%) after 8 hours, in contrast the marketed formulation released (44.8%) of the drug after 8 hrs. 
The in vitro Miconazole nitrate release data were fitted to Korsmeyerpeppa's release model. The 
formulation exhibited non-fickian transport with zero order kinetics. Formulae G1, G8 and G10, that 
showed both small droplet size and highest extent of drug release, were microbiologically evaluated 
against Candida albicans (C. albicans) using agar cup diffusion method. The selected formulae 
showed superior antimycotic activity compared to the commercially available formulation. 
Keywords: Cubosome, Miconazole, Candida albicans, Cubogel, Topical delivery, Nanoemulsion.
Introduction 
Miconazole nitrate is an imidazole derivative characterized by 
longer half-life and higher efficacy  in the treatment of the protozoal 
and anaerobic bacterial infection of the vagina [1]. Miconazole  
nitrate (MN) is a broad-spectrum antifungal agent of the imidazole 
group. It acts inhibiting  ergosterol biosynthesis, which causes lysis 
of fungal cell membranes because of the changes in both  
membrane integrity and fluidity and direct membrane damage of 
the fungal cells [2]. The drug is  primarily used as a topical 
treatment for cutaneous mycoses; poor dissolution and lack of 
absorption  make it a poor candidate for different route of 
administration. However, MN can be used as a systemic antifungal 
agent when amphotericin B or ketoconazole is either ineffective or  
contraindicated. MNÊs poor skin penetration capability presents a 
problem in the treatment of cutaneous diseases by topical 
application [3]. The stratum corneum is the target organ of anti-
mycotic treatment, and the improvement of local bioavailability  
 
 
leads to enhanced efficacy of the applied formulation. For effective 
treatment, the drug must be delivered in sufficient concentration  
1to the site of infection. Various approaches have been used to 
enhance the access of such poorly skin-partitioned drug molecules. 
Several reports have described the potential use of cubosomes in  
order to deliver drugs into the deep layers of the skin [3]. The aim 
of this study was to develop topical cubosomal dispersions loaded 
with Miconazole nitrate. The cubosomes were prepared by hot 
high-pressure homogenization method and were characterized in 
terms of particle size, morphology and in-vitro drug release 
followed by the incorporation of the optimal cubosomal dispersion 
in CMC or HPMC hydrogels (cubogels).The influence of the  
cubogels on ex-vivo drug skin permeation was evaluated and 
compared with a conventional gel. The emulsification of the cubic 
lipid phases in water results in the production of cubosomes that 
can be defined as nanoparticulate dispersal systems characterized 
by high biocompatibility and bioadhesivity [4]. Cubosomes are 
bicontinuous cubic phase liquid crystals have many properties that 
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make them appealing as a universal vehicle for drug delivery [5]. 
The surfactant assembles into bilayers that are twisted into a three 
dimension, periodic, minimal surface forming tightly packed 
structure, like „honeycombed‰ with bicontinuous domains of water 
and lipid. In the field of drug delivery, the bicontinuous cubic 
phases, particularly cubosomes, are promising vehicles since they  
are bioadhesive and have a property for controlled drug release [6]. 
They are capable of incorporating both hydrophobic and 
hydrophilic drugs and are found to protect drugs from degradation 
[7]. Cubosome could also enhance the drug deposition in the skin 
and showed excellent skin targeted characteristics [8]. 
Manufacturing Of Cubosomes  
Cubosomes can be manufactured by two distinct methods [9 
And10]. 
Top down Technique  
Bulk cubic phase is first produced and by application of high 
energy such as high pressure  homogenization, it is processed into 
cubosomes nanoparticles. Bulk cubic phase resembles a clear rigid 
gel formed by water-swollen cross-linked polymer chains. The 
cubic phases differ in that they are a single thermodynamic phase 
and have periodic liquid crystalline structure. Cubic phases 
ruptures in a direction parallel to the shear direction, the energy 
required is proportional to the number of tubular network branches 
that rupture.  
Bottom up Technique 
 In this cubosomes are allowed to form or crystallize from 
precursors. The bottom-up approach first forms the nanostructure 
building blocks and then assembles them into the final material. It 
is more recently developed technique of cubosome formation, 
allowing cubosomes to form and crystallize from precursors on the 
molecular length scale. The key factor of this technique is 
hydrotrope that can dissolve water insoluble lipids into liquid 
precursors. This is a dilution based approach that produces 
cubosomes with less energy input when compared top down 
approach. 
 
Materials and Methods 
Materials 
Miconazole nitrate was kindly donated as a gift from Medical union 
Pharmaceuticals company, Cithrrol ® HP-SO-(LK) RV06530 was 
used as the source of GMO and Synperonic (PE/F127) Flakes 
[Poloxamer 407 (P407)], were kindly supplied as a gift from croda. 
Polyvinyl alcohol, Polyethyleneglycol 400, propylene glycol, 
HPMC15000 were obtained from Sigma Chemical Co. (St. Louis, 
USA). Ethanol was purchased from ADWIC, (Egypt). Miconaz® 
skin cream (Miconazole nitrate 2% w/w, manufactured by Medical 
union Pharmaceuticals) was purchased from a local pharmacy 
store. All other materials were of analytical grade. 
Methods 
Preparation of MN loaded cubosomes Preparation of cubosome 
dispersions was based on the emulsification of 
monoglyceride/surfactant mixtures in water [11]. In particular, the 
monoglyceride based lipidic phase was glyceryl monooleate. 
Poloxamer 407 was used as surfactant in ratio to glyceryl 
monooleate of 1:9, 1:6, 1:3 and 1:15. The concentration of the 
glyceryl monooleate/surfactant mixture was 5% w/w with respect to 
the total weight of the dispersion. Composition of prepared MN 
loaded cubosomes is presented in table 1. PVA and PG were used 
in addition to poloxamer as a stabilizing agent for the dispersion, 
and it was added by solubilization at 80 ĈC in the aqueous phase in 
concentration of 2.5% w/w with respect to the disperse phase. 
Briefly, GMO and Poloxamer 407 were melted on a hot plate. MN 
was dispersed in the molten mixture. The molten mixture was then 
added dropwise to the aqueous phase at 70 ĈC under mechanical 
stirring at 1500 rpm [12]. Dispersions were maintained under 
stirring for two hours, afterwards the dispersions were subjected to 
homogenization at 15000 rpm at 60 ĈC for one minute and then 
were cooled to room temperature up to the solidification of lipid 
droplets [13]. Dispersions were stored in glass bottles at room 
temperature for further investigations. 
In vitro characterization of prepared MN loaded 
cubosomes 
Determination of MN content 
MN loaded cubosomes were mixed with methanol and sonicated 
for 10 min to obtain a clear solution [11]. Concentrations of MN 
were determined spectrophotometrically λmax 272 nm. 
 
                           
ࡰ࢛࢘ࢍ ࡯࢕࢔࢚ࢋ࢔࢚ ൌ
࡭ࢉ࢛࢚࢛ࢇ࢒ ࢅࢋ࢏࢒ࢊ
ࢀࢎࢋ࢕࢘࢏࢚࢏ࢉࢇ࢒ ࢅࢋ࢏࢒ࢊ
܆ ૚૙૙ 
 
 
 
 
 
 
Khalifa,  International Journal of Drug Delivery 7 (1) 01-12 [2015] 
 
 
  
PAGE | 3 |
 
           Table 1. Composition of prepared MN loaded cubosomes 
 
 
Particle size analysis of cubosomes 
Particle size analysis of the dispersions was performed using a 
Zetasizer 3000 PCS (Malvern Instr., England) equipped with a 5 
mW helium neon laser with a wavelength output of 633 nm.  
Measurements were made at 25ĈC, angle 90Ĉ, run time at least 180 
sec. Data interpreted by the method of cumulants. 
High Resolution Transmission electron microscopy 
(HRTEM) 
The samples were prepared by placing 5 μl droplet of the prepared 
dispersion onto a 300 mesh carbon coated copper grid, and 
allowing cubosomes to settle for 3ă5 min. Excess fluid was then  
removed by wicking it off with an absorbent paper. The samples 
were then viewed on a JEOL Model- (JEM- 2100) 200KV 
transmission electron microscope with resolution of 0.1432 nm and 
magnification power of 1.5 M. 
In vitro release of MN from prepared cubosomes and 
the kinetic analysis of the data 
The in-vitro release of miconazole nitrate from different cubosomes 
was performed using the dialysis method [1]. The semipermeable 
cellophane membrane was obtained from Sigma which has a 
molecular wt cut off 12,000 Daltons  was previously soaked in 
phosphate buffer of pH 6.4 and dried, and was stretched over the 
open end of a glass tube having a diameter of 3 cm. An amount of 
MN cubosomes equivalent to 50 mg drug was spread on the 
membrane to occupy all 3 cm diameter circle. The tubes were then 
immersed upside ă down in a 250 ml beaker containing 100 ml  
phosphate buffer pH 6.4 which is preheated and maintained at 37 
μ 1ÀC in a constant temperature water bath. The tubes height was 
adjusted so that the membrane was just below the surface of the 
release medium. The whole assembly was shaken at 50 rpm 
during the entire time of diffusion. For each gel sample, 3ml was 
withdrawn at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 and 24 hours´ 
time intervals and replaced by equal volumes of fresh release 
medium maintained at the same temperature. Samples were 
measured spectrophotometrically at λmax 272 nm against the 
same used phosphate buffer as a blank using Jenway 
spectrophotometer (Model 6105UV/Vis, Eng-land). The amounts of 
drug released were calculated on the basis of the standard curve 
previously constructed. Sink condition was maintained throughout 
the experiment. To study the drug release mechanism of each 
formulation, the release data were fitted to the general 
exponentional function: Mt / M0 = ktn; where Mt / M0 represents 
the fractional uptake of solvent (or release of a solute) normalized 
with respect to the equilibrium conditions; n is a diffusion exponent 
characteristics of the release mechanism, and k denotes properties 
of the polymer and the drug. This equation has been used 
frequently, due to its utility in describing the relative importance of 
Fickian (n = 0.5) and Case II (n ª 1.0) transport in anomalous 
diffusion. Kinetic studies were performed by adjusting the release 
profiles to Higuchi and zero order equations [14]. 
Preparation of hydrogels loaded with MN cubosomes 
(cubogels) 
Cubogels were prepared by sprinkling HPMC (1.5% w/v) or CMC 
(2%w/v) over a specified amount of liquid cubosome dispersion 
and stirred with mechanical stirrer. Propyl paraben sodium salt 
(0.1% w/w) was added as a preservative to the preparation. Stirring 
was continued until a thin hazy dispersion, without lumps, was 
formed. For complete gel dispersion it was necessary to leave 
samples overnight in the refrigerator [14]. For cubogels containing 
5% PEG or PG, they added to the dispersion followed by the 
addition of gelling agent. The compositions of the prepared 
cubogels are shown in table 2. 
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           Table 2. Compositions of the prepared cubogels 
 
   A All formulae contained 2% MN.
In vitro characterization of prepared cubogels 
Evaluation of the physical properties of the prepared 
cubogels 
Determination of pH 
The pH of cubogels was measured on digital pH meter 
standardized using pH of 4.0 and 7.0 standard buffers before use 
[14]. 
Drug content studies 
The drug content studies of MN cubogels were investigated as 
prescribed previously. 
Viscosity measurement 
A Cole parmer viscometer was used to measure the viscosity of 
the prepared gel bases. The spindle was rotated at 10 rpm. 
Samples of the bases were allowed to settle over 30 min at room 
temperature before the measurements were taken [14]. 
In vitro release of MN from the prepared cubogels and kinetic 
analysis of the release results 
The in vitro release studies of MN cubogel were investigated as 
prescribed previously. In vitro drug release from commercial 
product Miconaz® was carried out using the same procedure. 
Ex vivo permeation of MN cubogels, through rabbit skin  
Preparation of a rabbit skin  
Dorsal full-thickness skin of male rabbit was obtained from white 
Newzealand rabbits weighing 3-4 kg. The skin was carefully 
removed from animals and after sacrificing them, the hair was 
clipped without damaging the skin. The fat was removed with the 
aid of scissor and skin was washed and the excised full thickness 
rabbit skin samples were stored at 20oC prior to use [15]. The 
excised full thickness rabbit skin samples were equilibrated by 
soaking in buffer solution of pH 6.4 for about one hour before 
beginning of each experiment.  
Ex vivo permeation studies  
The first three formulations that gave best Q (the cumulative 
amount of drug penetrates through the unit surface area of the 
membrane) after 24 hours were chosen for in vitro permeation 
studies of MN through dorsal rabbit skin. The same procedure for 
testing permeation through cellulose membrane was applied with 
the exception that the prepared skin samples were mounted on the 
donor compartment of the assembled permeation cell with the 
stratum conium facing upward and the dermal side facing 
downward with permeation area of 3.14cm2. The donor 
compartment was kept hanged on the receptor compartment and 
secured tightly with the help of clamps. The receptor compartment 
was then filled with 100 ml of phosphate buffer solution of pH 6.4. 
The temperature of media was maintained at 37μ0.5oC. The 
amount of drug permeated through rabbit skin per unit area 
(μg/cm2) was plotted against time (hours) [15]. 
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Calculation of permeation parameters across rabbit skin  
Different permeation parameters of MN was calculated such as 
steady state fluxes (Jss) that were calculated from the slope of the 
portion of the amount permeated through unit area of the rabbit 
skin versus time plot (14). Permeability coefficient (Kp) through 
rabbit skin, Diffusion coefficient (D) within the rabbit skin and lag 
time (tL) were calculated from the penetration data.  
Microbiological study of MN 
The agar medium was prepared by dissolving 65 gm of sabouraud 
dextrose agar powder per liter of distilled water and was sterilized 
using autoclave at 121ĈC for 20 min. The indicator isolate of 
Candida albicans (ATCC 90028) was inoculated into sabouraud's 
dextrose agar plate and was incubated for 48 hr prior to testing. 
Once actively growing colonies of Candida albicans is obtained, a 
single well isolated colony was picked with a wire loop from 
sabouraud's dextrose agar plate and inoculated in sterilized normal 
saline and its turbidity is adjusted to match that of standard of 0.5M 
McFarland barium sulfate, so that it contains approximately 107 
cells/ml. The isolate of Candida albicans was seeded from 
standardized suspension to a concentration of 3 μl per ml in agar 
medium, the seeded agar medium was poured into Petri-dishes 
(15cm diameter) to a depth of about 4mm and numbers of wells in 
each dish were cut using Wassermann tube of 6mm diameter. The 
antifungal efficacy of MN cubogels and commercial MN cream 
(Miconaz®) was determined by performing agar-cup diffusion 
assay.  The effectiveness of the prepared MN cubogels against 
Candida albicans was studied, by applying 0.4 gm of the gel and 
an equivalent weight of commercial cream on the sabouraud 
dextrose agar which was previously seeded with Candida albicans. 
The Petri dishes were then incubated at 25OC.The effectiveness of 
the prepared gel was compared with plain gel contains 0% of MN 
and the commercial MN cream Miconaz®. The zones of growth 
inhibition were measured for all the tested samples. Each type of 
the samples was tested in triplicate [16]. The inhibition zone of 
growth of Candida albicans was measured in mm after 24 and the 
mean inhibition zone was then calculated. 
Statistical analysis 
Statistical analysis of the results was performed using one-way 
analysis of variances (ANOVA) to determine the significance of 
differences between groups; a P value less than 0.05 was 
considered statistically significant. 
Results and discussion  
Determination of MN content 
Drug content was determined in order to make sure that the added 
amount of MN is present in the cubosome dispersion. Cubosome 
dispersions had drug content ranging from 86.6% to 94.56% of the 
added amount of MN as shown in table 3.  
 Table 3. Drug content, Z-average and PDI of measured cubosomes (n = 3) Particle size analysis of cubosomesParticle 
size measurement was done to confirm that particles of the 
dispersion are all of nanometer range. Z-average of all the 
measured dispersions is shown in table 3. Z-average of all 
dispersions was in the nanometer range (average particle size 
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values ranged from 128.9 nm to 501.4 nm), with a polydispersity 
index of < 1. The cubosomes of diameter ª 100 nm are considered 
small cubosomes while those of diameter > 200 nm are larger 
cubosomes [12]. The addition of PVA as a stabilizer at ratio of 
2.5% resulted in a significant increase in particle size at p < 0.05(> 
200 nm for D5 and D9) as shown in table 3, although the increase 
in surfactant concentration  with PVA ( 2.5 %) results in a 
significant decrease at p <0.05 in the particle size again. This result 
is in agreement with the results obtained by Esposito et al [13].The 
addition of PG at ratio of 2.5% resulted in a significant increase in 
particle size (D 10, D11, D12 and D13).Results of the one-way 
ANOVA showed that the total concentration of surfactant and PVA 
had significant effect on the average particle size (Z-average 
(d.nm)) of cubosomes (p < 0.05). 
High Resolution Transmission electron microscopy 
(HRTEM) 
The high resolution transmission electron micrographs showed that 
the investigated cubosome (D1) is in the nano-size, which confirms 
the results of particles size measurement (figure 1). Micrographs 
reveal the coexistence of the particles and vesicles characterized 
by cubic organization and well separated from each other.  
 
 
Figure 1. High resolution transmission electron micrographs of cubosome dispersions (D1); (a) 50 kx, (b) 20 kx and (c) 1500 kx, the cubosomes 
are cubic in shape, nano-sized and well separated from each other. 
 
In vitro release of MN from prepared cubosomes and 
the kinetic analysis of the data 
In vitro release profile of MN from cubosomes was performed in 
Phosphate buffer at pH of 6.4 using the dialysis method as shown 
in figure2. The release of MN from its solution was very slow; it 
releases about 6.8% after 7 h. The dispersion containing PVA (D5, 
D6, D9 and D14), about 21, 44.8, 9.8 and 15.9 % respectively of 
MN was released during the first 7hrs, The addition of PVA 
resulted in significant decrease in the percent of drug released 
after 2, 4 and 7 hours at p < 0.05, as demonstrated in figure 2b. 
This result is in agreement with the results of Morsi et al [11]. PVA 
is a polyol which is known to be an excellent size controlling agent 
and stabilizer [11]. For the dispersion (D1, D7, D8 and D10) which 
A B
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contain no PVA, about 100.52, 100.8, 98.28 and 70.28 % 
respectively of MN was released during the first 7hrs.  
The in vitro release characteristics of percutaneous cubosomes 
showed that the drug release is directly proportional to the 
concentration of GMO and inversely proportional to the 
concentration of P-407 i.e. the cubosomes showed decrease in 
percent drug release when using of lower concentration of GMO 
and higher concentration of P-407 polymer. It was found that in the 
presence of less poloxamer 407 concentration, cubic particles 
exists in Pn3 m (CD) patterns, it has been observed that at low 
concentration of Poloxamer 407, most of the polymer adheres to 
the surface of cubosome particles and a few participate in the 
formation of the internal cubic structure [17]. At high poloxamer 407 
concentrations, the polymer is incorporated into the bulk of the 
cubic-phase matrix and Im3 m (CP) patterns appear in the 
dispersions. It is suggested that the cubic particles with cP 
structure have lower drug release efficiency, and the drug release 
is more restricted than that of the particles with cD structure [18]. 
Dispersion containing oleic acid (D3andD4) showed a significant 
reduction in drug release percent (13.3 and 25.2% respectively) at 
p< 0.05 after 7 hours. This is may be due to an increase in 
lipophilicity in the formulation which attracts the hydrophobic drug 
towards itself leading to slow release from the nanoparticles [8]. 
Kinetic studies for drug release from different 
dispersions 
The kinetic analysis of the release data is shown in table 4, and it 
can be observed that the release of most formulae (D1, D3, D4, 
D6, D7, D9, D10, D12 and D13) exhibited non- Fickian transport 
according to Korsmeyerpeppa's release model.  And most of 
formulae followed zero ăorder kinetics (D1, D3, D6, D7, D9, D10, 
D12, D13 and D14) as indicated from the highest coefficient of 
determination (r).  
 
 
Figure 2. In vitro release profiles of (a) stabilizer free cubosomes, (b) PVP 2.5% cubosomes and (c)PG 2.5% cubosomes in comparison with 
control (Miconazole nitrate solution 2%) 
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Table 4. Kinetic studies for drug release from different dispersions 
Preparation of hydrogels loaded with MN cubosomes 
(cubogels) 
Determination of pH 
The pH of cubogels was found to be in the range of 5.2 to 6.2 
(table 5) which was within the acceptable limits for topical 
application. 
Drug content studies 
Cubogels had drug content ranging from 85.9% to 93.12% of the 
added amount of MN 
Viscosity measurement 
The viscosity of semisolid preparations plays an important role in 
drug release from the vehicles and greatly affects drug 
bioavailability (19).  The viscosity of the cubogels could be 
observed from table (5). Viscosity was ranged from 348.3 to 633.5 
Ps.  
           Table5. Viscosity and pH of the prepared cubogels 
In vitro release of MN from prepared cubogels and the 
kinetic analysis of the data 
The in vitro release results of MN from different cubogels in 
comparison with commercial MN cream (Miconaz®) are 
represented in figure 2. Percent MN released after 2 h can be 
arranged in a descending order: G8 (48.44)> Miconaz ® (25.2) > 
G1 (22.4) = G10 (22.4) > G9 (17.64) > G15 (15.4). Percent MN 
released after 4 h can be arranged in a descending order: G8 
(81.2) > G1 (50.4) > G10 (33.6) > Miconaz ® (28.84) > G4 (25.2). 
While Percent MN released after 8 h can be arranged in a 
descending order: G8 (100) = G1 (100) > G5 (74.76) > G6 (70.56) 
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> G10 (51.24) >Miconaz ® (44.8). It was found that G1 and G8 
showed a significant high percent MN released in comparison with 
other cubogels and commercial MN cream Miconaz® at p < 
0.05.The kinetic analysis of the release data is shown in table 5, 
and it can be observed that the release of most formulae (G1, G3, 
G4, G5, G6, G11, G12, G15and G16) exhibited non- Fickian 
transport according to Korsmeyerpeppa's release model.  And 
most of formulae followed zero ăorder kinetics (G2, G3, G4, G6, 
G7, G9, G10, G11, G12, G13, G14 and G15) as indicated from the 
highest coefficient of determination (r).  
 
 
 
Figure 3 (a and b). In vitro release profiles cubogels in comparison with commercial MN cream (Miconaz®) 
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Table 6. The kinetic analysis of MN release from the prepared cubogels 
Ex vivo Permeation of MN cubogels, through Rabbit 
Skin 
Permeation results of MN from different gel bases and commercial 
MN cream (Miconaz®) using dorsal rabbit skin are shown in figure 
4. It was found that the permeation of MN through dorsal rabbit 
skin from all gel bases was significantly higher than that obtained 
from the commercial MN cream. Archana et al. found that the 
hydrogels with cubosomes showed better permeability when 
compared to the hydrogels with pure drug. This shows that 
cubosomes enhance the permeability of the drug [20]. 
Calculation of Permeation Parameters for MN 
formulations using rabbit skin  
The permeation data were treated according to zero order or 
membrane diffusion controlled model and the permeation 
parameters calculated according to FickÊs law, like flux (Jss), 
Diffusion Coefficient (D), Permeation Coefficient (P) and Lag time 
(tL) were obtained. Permeation parameters obtained, according to 
FickÊs law are shown in table 7. The flux coefficient values of G1, 
G8 and G10 were significantly higher than that of commercial MN 
formulation at p < 0.05.  
 
 
              Figure4. Ex vivo permeation of MN cubogels in comparison with commercial MN cream (Miconaz®) 
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     Table 7. The permeation parameters of MN cubogels in comparison with commercial MN cream (Miconaz®) 
 
Microbiological study of MN 
The cubogel formulations (G1, G8 and G10) were further evaluated 
for antifungal activity against Candida albicans by agar cup 
method. The results of zone of inhibition of MN cubogels were 
compared to the commercial (Miconaz® cream). The zones of 
inhibition of various formulations are represented graphically in 
figure 5. These results demonstrated that, the antifungal activity of 
the cubogel formulations were significantly higher than that of the 
commercial product although there is no significant differences 
between the prepared cubogel formulations (p<0.05). No 
significant zone of inhibition was observed in case of plain gel 
which contain 0% of MN which indicates that the components of 
micro emulsion, except miconazole nitrate, have no antifungal 
activity. cubosomes acts as carriers for drug delivery to the 
particular site of action, the antifungal activity is created by the drug 
incorporated into the cubosomes. This enhanced antifungal activity 
is due to enhanced penetration of cubosomes containing drug 
through the fungal cell wall and inhibiting the ergosterol synthesis 
[21]. The greater in vitro antifungal activity of cubogels than 
marketed cream may be due to the smaller globule size with its 
larger surface area as compare to the normal emulsion present in 
the cream. This may be the reason for greater drug release from 
cubogels preparation [22].  
 
 
Figure 5. Histogram showing the mean values of inhibition zones of MN cubogels and its commercial cream at 24 hrs. 
Conclusion 
In this work, cubogels were formulateded to deliver Miconazole 
Nitrate for topical administration. From in-vitro release, ex vivo 
permeation and microbiological study data it can be concluded that 
the developed cubogels have a great potential for topical drug 
deliver
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